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Abstract
Background: Recently, maintaining higher relative dose intensity (RDI) of chemotherapeutic
drugs has become a widespread practice in an attempt to achieve better outcomes in the treatment
of aggressive lymphoma. The addition of rituximab to chemotherapy regimens has significantly
improved outcome in diffuse large B-cell lymphoma (DLBL). However, it is unknown if higher RDI
in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell
lymphoma.
Methods: We retrospectively evaluated the impact of the RDI of initial chemotherapy (consisting
of cyclophosphamide, doxorubicin, vincristine and prednisolone with rituximab (R-CHOP) on
outcome in 100 newly diagnosed DLBL patients.
Results: A multivariate Cox regression model showed that RDI trended towards a significant
association with mortality [hazard ratio per 0.1 of RDI = 0.8; 95% confidence interval 0.6–1.0; P =
0.08]. Additionally, on multivariate logistic analysis, advanced age was a significant factor for
reduced RDI.
Published: 19 August 2009
Journal of Experimental & Clinical Cancer Research 2009, 28:116 doi:10.1186/1756-9966-28-116
Received: 1 May 2009
Accepted: 19 August 2009
This article is available from: http://www.jeccr.com/content/28/1/116
© 2009 Terada et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Cancer Research 2009, 28:116 http://www.jeccr.com/content/28/1/116
Page 2 of 6
(page number not for citation purposes)
Conclusion: Our data suggest that in DLBL patients, mortality was affected by RDI of R-CHOP
as the initial treatment, and the retention of a high RDI could therefore be crucial.
Background
Aggressive lymphoma is known to be a highly chemosen-
sitive disease. Therefore, over the past few decades, con-
stant attempts have been made to develop various types of
combination chemotherapy including first generation
combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) [1].
However, particularly in patients with aggressive lym-
phoma in the higher International Prognostic Index (IPI)
risk group, satisfactory outcomes have not been achieved,
with a five-year survival of less than 50% [2].
Several retrospective studies demonstrated that the rela-
tive dose intensity (RDI) of combination chemotherapy
significantly influences survival in aggressive lymphoma
[3-7].
Moreover, rituximab, a chimeric monoclonal anti-CD20
antibody combined with CHOP chemotherapy (R-
CHOP) has improved outcome in patients with diffuse
large B-cell lymphoma (DLBL) [8,9]. Rituximab has
direct, complement-dependent and antibody-dependent
cellular cytotoxicity against B-cells. The drug also sensi-
tizes B-lymphoma cells to chemotherapy [10]. Therefore,
a combined approach with rituximab plus CHOP could
conceivably modify the effects of RDI. However, there is
no evidence that even in combination chemotherapy with
rituximab that higher RDI improves the outcome for
aggressive B-cell type lymphoma. Hence, in our study, we
retrospectively analyzed the impact of the RDI of chemo-
therapy with R-CHOP as an initial treatment on the sur-
vival of patients with DLBL, and furthermore, we
determined the factors influencing RDI.
Methods
Eligibility
Patients were eligible if they had newly diagnosed DLBL
according to the World Health Organization classification
or the Revised European-American Lymphoma classifica-
tion [11,12]. As initial chemotherapy, they received R-
CHOP with more than three consecutive courses between
December 2003 and February 2008 at five institutions,
Osaka City University Hospital, Osaka City General Hos-
pital, Seichokai Fuchu Hospital, Saiseikai Nakatu Hospi-
tal and Wakakoukai Hospital. One hundred patients who
had complete records of drug dose, time intervals, and
prophylactic G-CSF use were deemed eligible for this
study. Patients were excluded if they had T-cell lymphoma
or prior radiotherapy before CHOP. Clinical data and fol-
low-up information were obtained by reviewing the
patients' medical records. All patients provided written
informed consent for their treatment.
Patient Characteristics
We analyzed 100 newly diagnosed DLBL patients treated
with initial R-CHOP chemotherapy. The clinical charac-
teristics of all the patients are shown in Table 1. Median
age of the patients was 60 years. Of the 100 patients, 45
were 61 years or older. Sixty-two patients had advanced-
stage (stage III, IV) disease, and 23 patients had poor per-
formance status (PS). In 52 patients, lactate dehydroge-
nase level (LDH) was high (over the upper limit of
normal). Thirty-two patients had two or more extranodal
disease sites. Forty-two patients were in the higher IPI risk
group (high or high-intermediate risk group). In 26
patients, serum albumin levels were < 3.5 g/dl. The
median number of CHOP courses was 6 (range, 3–8). The
median number of R-CHOP cycles for patients with local-
ized disease was 6 (range, 3–8), and there was no signifi-
cant difference in the number of cycles between patients
with localized disease and those with advanced disease.
Table 1: Patient characteristics
n. (%)
Total number of patients 100
Age
< 61 55 (55)
≥ 61 45 (45)
Clinical Stage
I, II 38 (38)
III, IV 62 (62)
Performance status
0–1 77 (77)
2–4 23 (23)
LDH
N≥ 52 (52)
N < 48 (48)
Extranodal lesion
0–1 68 (68)
2–4 32 (32)
IPI
Low/low-intermediate 58 (58)
High/high-intermediate 42 (42)
Albumin
< 3.5 g/dl 26 (26)
≥3.5 g/dl 74 (74)
Prophylactic G-CSF
yes 62 (62)
no 38 (38)
N: normal range; IPI: international prognostic index; G-CSF: 
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Chemotherapy Regimen
The CHOP chemotherapy consisted of cyclophosphamide
(750 mg/m2 given intravenously on Day 1), doxorubicin
(50 mg/m2 given intravenously on Day 1), vincristine (1.4
mg/m2 (maximum 2 mg/body), given intravenously on
Day 1) and prednisolone (100 mg/day, given orally on
Day 1 to 5) [13]. The treatment course was repeated every
three weeks, unless peripheral leukocyte or platelet counts
became too low to administer the next cycle. A time limit
for peripheral blood count recovery before administration
of the next cycle of chemotherapy was not adopted. In
patients who experienced severe neutropenia, thrombocy-
topenia and/or infections, or febrile neutropenia during
cycles, the doses of cyclophosphamide, doxorubicin and
vincristine in the subsequent cycle were reduced at the dis-
cretion of clinical physicians. Moreover, the dose of vinc-
ristine was also reduced depending on the occurrence and
degree of neurologic toxicity. Rituximab was administered
at a dose of 375 mg/m2 per cycle for up to 8 cycles concur-
rently with CHOP, as long as the disease responded to the
treatment. Seven patients received involved-field radia-
tion therapy of 30–40 Gy.
G-CSF was given if patients experienced neutropenia with
an absolute neutrophil count of less than 500/μl during
cycles. Prophylactic G-CSF was administered at the physi-
cian's discretion to prevent the development of neutrope-
nia in 62 patients who had experienced infections
associated with neutropenia in the prior cycle [14]. In
these patients, the median number of CHOP cycles with
prophylactic G-CSF was 3 (range, 1–6).
Calculation of Dose Intensity (DI)
The DI of each agent was calculated by dividing the total
received dose of the agent by the number of weeks of treat-
ment [3]. The relative total dose intensity (RTDI) of each
agent was calculated by expressing the total delivered dose
of agent per unit time (week) as a percentage of the target
dose. The averaged RDI (ARDI) was calculated by express-
ing the average delivered dose of the chemotherapy regi-
men per unit time (week) as a percentage of the target
dose. In this study, the ARDI was calculated by averaging
the RTDIs of cyclophosphamide and doxorubicin in all
the chemotherapy courses, and hereinafter the ARDI of R-
CHOP is simply referred to as the "RDI."
Statistical Methods
Overall survival (OS) was calculated from the initiation of
R-CHOP chemotherapy to the time of death or to the time
of the last follow-up. Progression free survival (PFS) was
calculated from the initiation of R-CHOP chemotherapy
to the time of relapse, progression, death or the last fol-
low-up. Both OS and PFS were calculated using the Kap-
lan-Meier method. Survival curves of the different groups
were compared using the log-rank test. Univariate and
multivariate Cox proportional hazard regression analyses
were used to assess the effects of the pretreatment prog-
nostic factors on overall survival [15]. Multiple logistic
analysis was applied to identify factors influencing RDI. P
values less than 0.05 were considered to be statistically
significant, and all tests were two-tailed. All analyses were
performed using SPSS version 15.0 J (SPSS, Chicago, IL).
Results
RDI
In all patients, the calculated medians of the RTDI of dox-
orubicin and cyclophosphamide were 88.8% and 88.6%,
respectively and the median RDI for all cycles of R-CHOP
given was 87.9%.
Survival Analysis
We registered 14 deaths. With a median follow-up of 21.2
months, the three-year OS in all cases, in the group with a
higher RDI (above the median) and in the group with a
lower RDI (below the median) was 81.6%, 92.1% and
74.2%, respectively (Figure 1). The three-year PFS in all
cases, in the group with a higher RDI (above the median)
and in the group with a lower RDI (below the median)
was 56.3%, 58.7% and 54.0%, respectively.
In the univariate analysis to identify prognostic factors for
OS, RDI and IPI were significant factors influencing OS. In
a multivariate analysis, RDI tended to be a significant risk
factor for mortality [hazard ratio (HR) per 0.1 of RDI =
0.8; 95% confidence interval (CI) 0.6–1.0; P  = 0.08]
(Table 2).
Factors Influencing RDI
The univariate analyses identified advanced age and
higher IPI score as risk factors for reduced RDI. In the mul-
tivariate logistic analysis of all these factors, only older age
Overall survival curves of the higher RDI (≥ median) and the  lower RDI (< median) group Figure 1
Overall survival curves of the higher RDI (≥ median) 
and the lower RDI (< median) group. RDI: relative dose 
intensity (RDI) of R-CHOP chemotherapy.
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remained as a factor that retained persistent statistical sig-
nificance [odds ratio (OR) = 0.4; 95% CI 0.2–0.8; P =
0.02]. (Table 3).
Discussion
In DLBL patients, our data demonstrated that a high RDI
of CHOP trended towards a significant association with
better survival, even when the CHOP was combined with
rituximab. Only advanced age was identified as a risk fac-
tor for reduced RDI.
There are several previous studies of the relationship
between the RDI of chemotherapy and survival in aggres-
sive lymphoma. A high RDI of doxorubicin in CHOP, M-
BACOD, or MACOP-B chemotherapy [4], a high RDI of
each drug (cyclophosphamide, doxorubicin or vincris-
tine) and a high averaged RDI of these three drugs in
CHOP for diffuse large cell lymphoma (DLCL) reportedly
had a significant, positive impact on survival [5]. In addi-
tion, in ACVB chemotherapy for aggressive lymphoma,
the averaged RDI of doxorubicin and cyclophosphamide
was strongly associated with survival [6]. Furthermore, it
was reported that in elderly patients with DLCL who
received a higher dose of doxorubicin, the outcomes were
comparable to those of young patients [16]. In a recent
study, a Belgian group also reported that maintaining a
high RDI resulted in a favorable outcome in CHOP chem-
otherapy for DLBL patients [7].
The addition of rituximab to CHOP or other chemother-
apy regimens has reportedly led to a significant improve-
ment in the prognosis of DLBL patients. Interestingly, it
was suggested from preclinical models that rituximab
chemosensitized drug-resistant B-lymphoma cells
through down-regulation of anti-apoptotic factors and
endogenous IL-10 expression [17,18], suggesting that
rituximab is likely to have a significant therapeutic effect
by augmenting the effect of anticancer agents in CHOP in
a synergistic fashion and thereby compensating for a low
CHOP RDI. However, from our results, it was clear that
Table 2: Prognostic factors for overall survival
Univariate model Multivariate model
Factor HR (95%CI) P value HR (95%CI) P value
Age (61 ≤) 2.2 (0.8–6.7) 0.15 - -
Sex (male) 2.6 (0.7–9.3) 0.14 - -
Stage III, IV 7.6 (1.0–5.8) 0.15 - -
Extranodal site (2 ≤) 1.7 (0.6–4.8) 0.35 - -
LDH (> upper normal limit) 1.8 (0.5–5.8) 0.34 - -
Performance status (2–4) 2.8 (1.0–8.1) 0.05 - -
RDI (CPA+DOX) per 0.1 0.7 (0.6–0.9) 0.02* 0.8 (0.6–1.0) 0.08
IPI (high/high intermediate) 4.7 (1.3–17) 0.02* 3.8 (1.0–14) 0.05
Albumin (3.5 mg/dl ≤) 0.7 (0.4–1.2) 0.20 - -
Prophylactic G-CSF 1.6 (0.5–4.9) 0.44 - -
HR: hazard ratio; CI: confidence interval; RDI: relative dose intensity; CPA: cyclophosphamide; DOX: doxorubicin; G-CSF: granulocyte colony-
stimulating factor
Table 3: Factors influencing RDI (above the Median): Univariate and Multivariate analysis
Univariate model Multivariate model 1 Multivariate model 2
Factor OR (95%CI) P value OR (95%CI) P value OR (95%CI) P value
Age (61 ≤) 0.3(0.2–0.8) 0.0099* 0.4 (0.2–0.8) 0.06 0.4 (0.2–0.8) 0.02*
Sex (male) 1.3 (0.6–2.9) 0.54 - - - -
Stage III, IV 0.8 (0.4–1.9) 0.68 - - - -
Extranodal site (2 ≤) 1.0 (0.4–2.3) 1.00 - - - -
LDH (> upper normal limit) 0.5 (0.2–1.2) 0.11 - - 0.6 (0.3–1.4) 0.24
Performance status (2–4) 0.6 (0.2–1.5) 0.24 - - - -
IPI (high/high intermediate) 0.4 (0.2–1.0) 0.04* 0.6 (0.3–1.6) 0.33 - -
Alb (3.5 mg/dl >) 0.8 (0.5–1.4) 0.50 - - - -
Prophylactic G-CSF + 1.7 (0.7–3.8) 0.22 - - - -
IPI: international prognostic index. G-CSF: granulocyte colony-stimulating factorJournal of Experimental & Clinical Cancer Research 2009, 28:116 http://www.jeccr.com/content/28/1/116
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maintaining a high RDI remained crucial in the use of R-
CHOP for DLBL patients, in a similar fashion to CHOP
alone.
We identified advanced age as the only factor that reduced
RDI. A nationwide study of RDI in CHOP-like chemother-
apies in patients with non-Hodgkin's lymphoma (NHL)
in the United States also showed that older age was a risk
factors for reduced RDI, in addition to lack of use of pro-
phylactic colony stimulating factor (CSF), advanced dis-
ease stage, poor PS and a lower serum albumin level [19].
Moreover, the study indicated that prophylactic CSF use is
important in maintaining a high RDI, particularly in eld-
erly patients. The American Society of Clinical Oncology
update guideline for the use of CSF, also recommends use
of prophylactic CSF during curative and intensive chemo-
therapy for elderly patients with DLCL, to reduce the inci-
dence of febrile neutropenia and infections [14]. In
addition, according to the European Organization for
Research and Treatment of Cancer guideline on the use of
G-CSF, when dose-dense or dose-intense chemotherapy
has a survival benefit, prophylactic G-CSF use is recom-
mended, especially in elderly patients [20]. Indeed, in a
prospective study on prediction of febrile neutropenia in
the first cycle of chemotherapy for NHL, elderly patients
were identified as candidates for primary CSF prophylaxis
[21]. Taking into account these reports as well as our
results, prophylactic use of CSF could be recommend, at
least in elderly patients with DLBL who are scheduled to
receive R-CHOP chemotherapy in order to maintain RDI.
As our study was a retrospective cohort study with a small
study population and/or short median follow-up periods,
it was inevitable that treatment bias due to physician dis-
cretion in making treatment decisions would arise. There-
fore, prospective randomized trials will be required to
confirm the value of maintaining a high RDI. For instance,
an alternative strategy to intensify RDI by shortening the
intervals between cycles of chemotherapy, such as bi-
weekly CHOP, may be promising [22]. Indeed, Groupe
d'Etudes de Lymphomes de L'Adulte (GELA) is now con-
ducting a phase III prospective randomized trial to assess
the difference between eight cycles of bi-weekly R-CHOP
and three-weekly R-CHOP. The results of this prospective
randomized trial are awaited.
Conclusion
In DLBL patients, mortality was affected by the RDI of R-
CHOP as the initial treatment and the retention of high
RDI could be crucial, especially in elderly patients. To
optimize the RDI of conventional chemotherapy in order
to achieve better outcomes for patients with DLBL, further
investigation of RDI will be required.
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